Gables Capital Management Inc. Buys Shares of 3,326 Thermo Fisher Scientific Inc. $TMO

Gables Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,326 shares of the medical research company’s stock, valued at approximately $1,668,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in TMO. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the period. J. Stern & Co. LLP lifted its position in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. State Street Corp raised its stake in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Finally, Capital World Investors lifted its holdings in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after buying an additional 718,669 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

TMO opened at $614.32 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a fifty day moving average price of $536.26 and a 200 day moving average price of $508.51. The stock has a market cap of $227.14 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 52,053 shares of company stock valued at $30,643,589. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on TMO shares. Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Royal Bank Of Canada raised their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.